Production of Furin‐Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1‐ or L2‐Specific Antibodies

Joshua W. Wang1, Ken Matsui1, Yuanji Pan2, Kihyuck Kwak3, Shiwen Peng4, Troy Kemp2, Ligia Pinto2, Richard B.S. Roden5

1 These authors contributed equally to this work, 2 Human Papillomavirus (HPV) Immunology Laboratory, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland, 3 Department of Pathology, The Johns Hopkins University, Baltimore, Maryland, 4 Department of Oncology, The Johns Hopkins University, Baltimore, Maryland, 5 Department of Gynecology and Obstetrics, The Johns Hopkins University, Baltimore, Maryland
Publication Name:  Current Protocols in Microbiology
Unit Number:  Unit 14B.5
DOI:  10.1002/9780471729259.mc14b05s38
Online Posting Date:  August, 2015
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

Immunization with Human Papillomavirus (HPV) L1 virus‐like particles or L2 capsid protein elicits neutralizing antibodies that mediate protection. A high‐throughput and sensitive in vitro neutralization assay is therefore valuable for prophylactic HPV vaccine studies. Over several hours during infection of the genital tract, virions take on a distinct intermediate conformation, including a required furin cleavage of L2 at its N‐terminus. This intermediate is an important target for neutralization by L2‐specific antibody, but it is very transiently exposed during in vitro infection of most cell lines resulting in insensitive measurement for L2, but not L1‐specific neutralizing antibodies. To model this intermediate, we describe a protocol to generate furin‐cleaved HPV pseudovirions (fc‐PsV), which deliver an encapsidated reporter plasmid to facilitate infectivity measurements. We also describe a protocol for use of fc‐PsV in a high‐throughput in vitro neutralization assay for the sensitive measurement of both L1 and L2‐specific neutralizing antibodies. © 2015 by John Wiley & Sons, Inc.

Keywords: furin‐cleavage; papillomavirus; antibody; human papillomavirus; HPV neutralization assay; HPV L2

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Introduction
  • Basic Protocol 1: Production of Furin‐Cleaved Pseudovirions (FC‐PSV)
  • Support Protocol 1: Assessment of Encapsidated Reporter Plasmid or Viral Genomic Equivalents (VGE)
  • Furin‐Cleaved HPV Pseudovirus Neutralization Assay (FC‐PBNA)
  • Basic Protocol 2: Performing FC‐PBNA with Secreted Alkaline Phosphatase
  • Alternate Protocol 1: Performing FC‐PBNA with Firefly Luciferase
  • Reagents and Solutions
  • Commentary
  • Literature Cited
  • Figures
  • Tables
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

Basic Protocol 1: Production of Furin‐Cleaved Pseudovirions (FC‐PSV)

  Materials
  • 293TTF cells (see Background Information)
  • 293TTF culture medium (see recipe)
  • Phosphate‐buffered saline (PBS; Invitrogen/Life Technologies, cat. no. 10010‐023)
  • 0.05% Trypsin/EDTA (Life Technologies, cat. no. 25300)
  • HPV types specific L1 and L2 vector plasmid and a reporter plasmid
  • Trypan blue
  • Mirus TransIT‐2020 transfection reagent (Mirus Bio, cat. no. MIR 5404)
  • 0.25% trypsin/EDTA
  • DPBS‐10 mM MgCl 2 with antibiotics (see recipe)
  • Lysis buffer (see recipe)
  • 1 M CaCl 2 (KD Medical, cat. no. PMS‐0614)
  • OptiPrep density gradient medium (60% w/v; Sigma, cat. no. D1556)
  • DPBS‐0.8 M NaCl (see recipe)
  • DPBS (Invitrogen/Life Technologies, cat. no. 14040)
  • Ice
  • DPBS with Mg++ and Ca++ (Invitrogen/Life Technologies, cat. no. 14287‐080)
  • 10× DPBS (Invitrogen/Life Technologies, cat. no. 14200‐075)
  • 1 M KCl (KD Medical, cat. no. PMB‐0730)
  • 1 M MgCl 2 (KD Medical, cat. no. PMS‐0630)
  • Distilled water (Invitrogen/Life Technologies, cat. no. 15230‐147)
  • 5 M NaCl (KD Medical, cat. no. RGF‐3270)
  • Brij58 (Sigma‐Aldrich, cat. no. P‐5884)
  • OptiMEM I reduced serum medium (Invitrogen/Life Technologies, cat. no. 11058‐021)
  • 225‐cm2 flasks (BD, cat. no. 353138)
  • 150‐cm2 flasks (Corning, cat. no. 430825)
  • 37°C, 5% CO 2 incubator
  • Microscope
  • 50‐ml conical tubes, sterile
  • Centrifuge (e.g.,Thermo Scientific Sorval Legend RT+)
  • Hemacytometer
  • Siliconized 1.5‐ml screw‐cap tubes (Fisher Scientific, cat. no. 05‐541‐63)
  • Microcentrifuge (e.g., Eppendorf Centrifuge 5417R); need to use it at 4°C
  • 1000‐μl pipets
  • 37°C water bath
  • Parafilm
  • Ultracentrifuge (e.g., Beckman Coulter Optima L‐80 XP Ultracentrifuge)
  • 15‐ml Polyallomer ultracentrifuge tubes (Beckman Coulter, cat. no. 331374) or 5‐ml Polyallomer ultracentrifuge tubes (Beckman Coulter, cat. no. 326819)
  • Swinging bucket ultracentrifuge rotor rated for >200,000 × g (e.g., SW55ti for 5‐ml tube or SW40ti for 15‐ml tube)
  • Siliconized pipet tips (VWR, cat. no.60828‐914)
  • Clamp ring or retort stand
  • 25‐G needles
  • 1‐ml TB syringe with 25‐G needle (BD, cat. no. 309626)
  • Pipetting needles with blunt end and standard hub (Popper and sons, cat. no. 7936)
  • Additional reagents and equipment for SDS PAGE (see ), immunoblotting (see unit ), cell counting with hemacytometer (see )
NOTE: Plasmids can be obtained from (Addgene: http://www.addgene.org/Richard_Roden or http://www.addgene.org/John_Schiller/)

Support Protocol 1: Assessment of Encapsidated Reporter Plasmid or Viral Genomic Equivalents (VGE)

  Additional Materials (also see protocol 1)
  • HPV fcPsV sample (see protocol 1)
  • PureLink Viral RNA/DNA extraction kit (Invitrogen, cat. no. 12280‐050)
  • Master mix (see Table 14.5.3) Known quantity (e.g., 5 to 50 nanograms) of reporter DNA to be utilized for the standard curve during qPCR analysis (e.g., SEAP: pYSEAP construct, or LUCIFERASE: pcDNA‐luciferase plasmid from: http://home.ccr.cancer.gov/LCO/plasmids.asp) Forward and Reverse Primers for SEAP/Luciferase plasmid (500 nM) including:
    • Luciferase Firefly Forward: TTG ACC GCC TGA AGT CTC TGA
    • Luciferase Firefly Reverse: ACA CCT GCG TCG AAG ATG TTG
    • SEAP Forward: GTA CCC AGA TGA CTA CAG CCA AG
    • SEAP Reverse: GGT GGA TCT CGT ATT TCA TGT CT
  • 96‐well plate for qPCR
  • Optical seals for qPCR plates (Microseal “B” Adhesive Seals, Optical; BioRad, cat. no. MSB‐1001)
  • Machine able to perform qPCR
Table 4.0.3   Additional Materials (also see protocol 1)Preparation of Master Mix for qPCR for Samples and/or Standards (e.g., the Reporter Plasmid Used for the fcPsV Production)

Mastermix 1× reaction per sample 2.2× reaction per sample of Standard 3.3× reaction per sample of Standard
EVAgreen Supermix (Bio‐Rad, cat. no. 172‐5200) 10 μl 22 μl 33 μl
Reporter gene's forward & reverse primers (500 nM) 1 μl 2.2 μl 3.3 μl
Sterilized dH 2O 6 μl 13.2 μl 19.6 μl
Reporter DNA template 3 μl 6.6 μl 9.9 μl
Total volume 20 μl 44 μl 66 μl

Basic Protocol 2: Performing FC‐PBNA with Secreted Alkaline Phosphatase

  Materials
  • LoVoT cells (see Background Information)
  • Assay medium (see recipe)
  • 1× PBS without Ca++ or Mg++ (Life Technologies, cat. no. 14190)
  • 0.4% trypan blue stain (Life Technologies, cat. no. 15250)
  • Furin‐cleaved pseudovirions (fcPsV) particles (see protocol 1)
  • Serum samples or antibody samples (See Critical Parameters)
  • Ziva Ultra SEAP Plus Detection kit (Jaden BioScience, cat. no. CM025) (see Background Information) containing:
    • SEAP Sample Preparation Solution (SSPS)
  • 5‐ and 10‐ml serological pipets (Costar, cat. no. 4051 and 4101)
  • Serological pipet filler (Thermo Scientific, cat. no. 9531)
  • 37°C, CO 2 incubator (Forma Scientific, Model 3110)
  • 50‐ml conical tubes (BD Falcon, cat. no. 352098)
  • Inverted light microscope (Nikkon TMS and Nikkon LBOPHOT)
  • Centrifuge (Thermo Scientific; Sorval Legend RT+)
  • Hemacytometer (Improved Neubauer 0.1‐mm deep)
  • 50‐ml reservoir troughs (Costar, cat. no. 4870)
  • Flat‐bottom 96‐well tissue culture plates (Costar, cat. no. 3596)
  • 10‐, 20‐, 100‐, 200‐, and 1000‐μl single or multichannel pipets (Rainin)
  • 10‐ to 1000‐μl pipet tips (Rainin, cat. no. SR‐L10S,‐250 S, and ‐L1000S)
  • Certified class II biological safety cabinet
  • Conical‐bottom, deep‐well, 96‐well plate (e.g., 0.5 to 2 ml; VWR, cat. nos. 40002‐022, ‐011, or ‐014); depending on the number of test‐wells, different size plates can be employed
  • Seal plate films (Thomas Scientific, cat. no. 6980A03)
  • 15‐ml conical tubes (Corning, cat. no. 430055)
  • Round‐bottom 96‐well tissue culture plates (Costar, cat. no. 3788)
  • V‐bottom 96‐well plates (Costar, cat. no. 3357)
  • Cold storage adhesive sealing foil (VWR, cat. no. 89049‐034)
  • −80°C freezer (Forma Scientific, Model 8517)
  • Plate shaker (e.g., Thermo Scientific titer shaker model 4625)
  • White opaque 96‐well microplate/OptiPlate‐96 (Perkin Elmer, cat. no. 6005290)
  • Oven capable of reaching 65° to 73°C (e.g., Thermo Scientific, Model Heratherm OMH100)
  • Aluminum foil
  • Plate reader capable of measuring luminescence (e.g., Molecular Devices, SpectraMax M5)
  • Computer and appropriate software to operate the plate reader

Alternate Protocol 1: Performing FC‐PBNA with Firefly Luciferase

  Additional Materials (also see Basic Protocols protocol 11 and protocol 32)
  • Dual‐Luciferase Reporter Assay System (Promega, cat. no E1910 or E1960) containing:
  • Cell Culture Lysis Buffer (Promega, cat. no. E1531)
  • 96‐well flat‐bottom tissue culture plates (Costar, cat. no. 3596)
  • Multichannel pipet
  • Black 96‐well optiplate (PerkinElmer, cat. no. 6005290)
  • Microplate Luminometer with an injector
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

Literature Cited
   Alphs, H.H. , Gambhira, R. , Karanam, B. , Roberts, J.N. , Jagu, S. , Schiller, J.T. , Zeng, W. , Jackson, D.C. , and Roden, R.B. 2008. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross‐neutralizing epitope of L2. Proc. Natl. Acad. Sci. U.S.A. 105:5850‐5855.
   Anderson, E.D. , Molloy, S.S. , Jean, F. , Fei, H. , Shimamura, S. , and Thomas, G. 2002. The ordered and compartment‐specific autoproteolytic removal of the furin intramolecular chaperone is required for enzyme activation. J. Biol. Chem. 277:12879‐12890.
   Anderson, E.D. , VanSlyke, J.K. , Thulin, C.D. , Jean, F. , and Thomas, G. 1997. Activation of the furin endoprotease is a multiple‐step process: Requirements for acidification and internal propeptide cleavage. EMBO J. 16:1508‐1518.
   Buck, C.B. , Pastrana, D.V. , Lowy, D.R. , and Schiller, J.T. 2004. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78:751‐757.
   Buck, C.B. and Thompson, C.D. 2007. Production of papillomavirus‐based gene transfer vectors. Curr. Protoc. Cell Biol. 37:26.1.1‐26.1.19.
   Buck, C.B. , Thompson, C.D. , Pang, Y.Y. , Lowy, D.R. , and Schiller, J.T. 2005. Maturation of papillomavirus capsids. J. Virol. 79:2839‐2846.
   Buck, C.B. and Trus, B.L. 2012. The papillomavirus virion: A machine built to hide molecular Achilles' heels. Adv. Exp. Med. Biol. 726:403‐422.
   Day, P.M. , Gambhira, R. , Roden, R.B. , Lowy, D.R. , and Schiller, J.T. 2008a. Mechanisms of human papillomavirus type 16 neutralization by l2 cross‐neutralizing and l1 type‐specific antibodies. J. Virol. 82:4638‐4646.
   Day, P.M. , Lowy, D.R. , and Schiller, J.T. 2008b. Heparan sulfate‐independent cell binding and infection with furin‐precleaved papillomavirus capsids. J. Virol. 82:12565‐12568.
   Day, P.M. , Pang, Y.Y. , Kines, R.C. , Thompson, C.D. , Lowy, D.R. , and Schiller, J.T. 2012. A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection‐inhibiting antibodies. Clin. Vaccine Immunol. 19:1075‐1082.
   Day, P.M. and Schiller, J.T. 2009. The role of furin in papillomavirus infection. Fut. Microbiol. 4:1255‐1262.
   Day, P.M. , Thompson, C.D. , Buck, C.B. , Pang, Y.Y. , Lowy, D.R. , and Schiller, J.T. 2007. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J. Virol. 81:8784‐8792.
   DiGiuseppe, S. , Bienkowska‐Haba, M. , Hilbig, L. , and Sapp, M. 2014. The nuclear retention signal of HPV16 L2 protein is essential for incoming viral genome to transverse the trans‐Golgi network. Virology 458‐459:93‐105.
   Gambhira, R. , Jagu, S. , Karanam, B. , Gravitt, P.E. , Culp, T.D. , Christensen, N.D. , and Roden, R.B. 2007a. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J. Virol. 81:11585‐11592.
   Gambhira, R. , Karanam, B. , Jagu, S. , Roberts, J.N. , Buck, C.B. , Bossis, I. , Alphs, H. , Culp, T. , Christensen, N.D. , and Roden, R.B. 2007b. A protective and broadly cross‐neutralizing epitope of human papillomavirus L2. J. Virol. 81:13927‐13931.
   Handisurya, A. , Day, P.M. , Thompson, C.D. , Buck, C.B. , Kwak, K. , Roden, R.B. , Lowy, D.R. , and Schiller, J.T. 2012. Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species. Virology 433:385‐394.
   Harro, C.D. , Pang, Y.Y. , Roden, R.B. , Hildesheim, A. , Wang, Z. , Reynolds, M.J. , Mast, T.C. , Robinson, R. , Murphy, B.R. , Karron, R.A. , Dillner, J. , Schiller, J.T. , and Lowy, D.R. 2001. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus‐like particle vaccine. J. Natl. Cancer Inst. 93:284‐292.
   Jagu, S. , Kwak, K. , Schiller, J.T. , Lowy, D.R. , Kleanthous, H. , Kalnin, K. , Wang, C. , Wang, H.K. , Chow, L.T. , Huh, W.K. , Jaganathan, K.S. , Chivukula, S.V. , and Roden, R.B. 2013. Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine. J. Virol. 87:6127‐6136.
   Kemp, T.J. , Hildesheim, A. , Falk, R.T. , Schiller, J.T. , Lowy, D.R. , Rodriguez, A.C. , and Pinto, L.A. 2008. Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti‐human papillomavirus type 16 antibodies. Clin. Vaccine Immunol. 15:60‐64.
   Kemp, T.J. , Hildesheim, A. , Safaeian, M. , Dauner, J.G. , Pan, Y. , Porras, C. , Schiller, J.T. , Lowy, D.R. , Herrero, R. , and Pinto, L.A. 2011. HPV16/18 L1 VLP vaccine induces cross‐neutralizing antibodies that may mediate cross‐protection. Vaccine 29:2011‐2014.
   Kemp, T.J. , Matsui, K. , Shelton, G. , Safaeian, M. , and Pinto, L.A. 2015. A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays. Hum. Vaccin. Immunother. 11:337‐346.
   Kirnbauer, R. , Booy, F. , Cheng, N. , Lowy, D.R. , and Schiller, J.T. 1992. Papillomavirus L1 major capsid protein self‐assembles into virus‐like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U.S.A. 89:12180‐12184.
   Kwak, K. , Jiang, R. , Wang, J.W. , Jagu, S. , Kirnbauer, R. , and Roden, R.B. 2014. Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types. PLoS One 9:e97232.
   Pastrana, D.V. , Buck, C.B. , Pang, Y.Y. , Thompson, C.D. , Castle, P.E. , FitzGerald, P.C. , Kruger Kjaer, S. , Lowy, D.R. , and Schiller, J.T. 2004. Reactivity of human sera in a sensitive, high‐throughput pseudovirus‐based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205‐216.
   Pastrana, D.V. , Gambhira, R. , Buck, C.B. , Pang, Y.Y. , Thompson, C.D. , Culp, T.D. , Christensen, N.D. , Lowy, D.R. , Schiller, J.T. , and Roden, R.B. 2005. Cross‐neutralization of cutaneous and mucosal Papillomavirus types with anti‐sera to the amino terminus of L2. Virology 337:365‐372.
   Roberts, J.N. , Buck, C.B. , Thompson, C.D. , Kines, R. , Bernardo, M. , Choyke, P.L. , Lowy, D.R. , and Schiller, J.T. 2007. Genital transmission of HPV in a mouse model is potentiated by nonoxynol‐9 and inhibited by carrageenan. Nat. Med. 13:857‐861.
   Roden, R.B. , Weissinger, E.M. , Henderson, D.W. , Booy, F. , Kirnbauer, R. , Mushinski, J.F. , Lowy, D.R. , and Schiller, J.T. 1994. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J. Virol. 68:7570‐7574.
   Wang, J.W. , Jagu, S. , Kwak, K. , Wang, C. , Peng, S. , Kirnbauer, R. , and Roden, R.B. 2014a. Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies. Virology 449:304‐316.
   Wang, J.W. , Jagu, S. , Wang, C. , Kitchener, H.C. , Daayana, S. , Stern, P.L. , Pang, S. , Day, P.M. , Huh, W.K. , and Roden, R.B. 2014b. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2‐based immunogens using furin‐cleaved HPV Pseudovirions. PLoS One 9:e101576.
   Wang, J.W. and Roden, R.B. 2013. L2, the minor capsid protein of papillomavirus. Virology 445:175‐186.
   Zhou, J. , Stenzel, D.J. , Sun, X.Y. , and Frazer, I.H. 1993. Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J. Gen. Virol. 74:763‐768.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library